Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

Shreyaskumar Patel, Margaret von Mehren, Damon R. Reed, Pamela Kaiser, John Charlson, Christopher W. Ryan, Daniel Rushing, Michael Livingston, Arun Singh, Rahul Seth, Charles Forscher, Gina D'Amato, Sant P. Chawla, Sharon McCarthy, George Wang, Trilok Parekh, Roland Knoblauch, Martee L. Hensley, Robert G. Maki, George D. Demetri

    Research output: Contribution to journalArticle

    5 Scopus citations

    Abstract

    Background: We performed a randomized phase 3 study of trabectedin versus dacarbazine in previously-treated patients with liposarcoma/leiomyosarcoma (LPS/LMS). Methods: Patients were randomized 2:1 to trabectedin (n = 384) or dacarbazine (n = 193) administered intravenously every 3 weeks. The primary objective was overall survival (OS). Secondary objectives were progression-free survival, objective response rate, safety, and patient-reported outcomes, all previously reported and demonstrating superior disease control with trabectedin. Results of the final OS analysis in preplanned subgroups of patients with LPS/LMS are presented. Results: At the time of the final OS analysis, 577 patients had been assigned randomly, including 423 (73%) with LMS and 154 (27%) with LPS. The median duration of treatment exposure was higher in the trabectedin arm compared with the dacarbazine arm (4 vs 2 cycles), as was the proportion of patients receiving an extended number of therapy courses (≥6 cycles: 42% vs 22%). This pattern was consistent across histological subgroups: the median number of treatment cycles (4 vs 2 for both subgroups) and proportion of patients with ≥6 treatment cycles (LMS, 43% vs 24%; LPS, 40% vs 16%). Despite improved disease control by trabectedin, no improvement in OS was observed; the final median OS for trabectedin versus dacarbazine was 13.7 versus 13.1 months (P =.49). Sensitivity analyses of OS suggest confounding by post-study anticancer therapies, which were utilized in most patients in both treatment arms (71% vs 69%, respectively). Conclusion: The final OS results demonstrated comparable survival between LPS/LMS patients receiving trabectedin or dacarbazine, which is consistent with the interim analysis results. Both LPS and LMS demonstrated improved disease control with trabectedin.

    Original languageEnglish (US)
    Pages (from-to)2610-2620
    Number of pages11
    JournalCancer
    Volume125
    Issue number15
    DOIs
    StatePublished - Aug 1 2019

    Keywords

    • dacarbazine
    • leiomyosarcoma
    • liposarcoma
    • soft tissue sarcoma
    • trabectedin

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma'. Together they form a unique fingerprint.

  • Cite this

    Patel, S., von Mehren, M., Reed, D. R., Kaiser, P., Charlson, J., Ryan, C. W., Rushing, D., Livingston, M., Singh, A., Seth, R., Forscher, C., D'Amato, G., Chawla, S. P., McCarthy, S., Wang, G., Parekh, T., Knoblauch, R., Hensley, M. L., Maki, R. G., & Demetri, G. D. (2019). Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer, 125(15), 2610-2620. https://doi.org/10.1002/cncr.32117